Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 51 Adjuvant in Patients With Advanced Solid Tumors

NCT06414733 is registered in ClinicalTrials.gov with Pravin T.P Kaumaya as lead sponsor.

NCT NCT06414733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06414733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 51 Adjuvant in Patients With Advanced Solid Tumors
Lead sponsor
Pravin T.P Kaumaya
Phase
Phase 1
Overall status
Recruiting
Start date
January 17, 2025
Completion date
December 31, 2030
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr overexpression, her-2 positive esophageal cancer, her2-positive breast cancer, metastatic breast cancer, metastatic esophageal carcinoma